Resonetics to Acquire Resolution Medical, Expanding Capabilities in Neuromodulation and Structural Heart Markets

Rhea-AI Summary

Resonetics (NYSE:CG) signed an agreement to acquire Resolution Medical, a designer and manufacturer of complex medical devices headquartered in Fridley, MN with operations in the Netherlands. The deal adds capabilities across neuromodulation, structural heart, and interventional cardiology and is expected to close in 2026, subject to regulatory approvals and customary closing conditions. Resolution Medical brings >240 employees, including >100 engineers, plus design engineering, NPI, and cleanroom production supporting Class II and III devices. Until closing both companies will operate independently.

Positive

• Adds capabilities in neuromodulation, structural heart, and interventional cardiology
• Acquires a team of 240+ employees including 100+ engineers
• Strengthens end-to-end offerings from design and NPI to cleanroom production
• Expected close in 2026, expanding Resonetics' full product lifecycle support

Negative

• Transaction is subject to regulatory approvals and customary closing conditions
• No purchase price or financial terms disclosed in the announcement
• Until close, operations remain independent, delaying immediate integration benefits

Key Figures

Employees added: more than 240 employees Engineering staff: over 100 engineers Expected close year: 2026

3 metrics

Employees added more than 240 employees Resolution Medical headcount contributed to Resonetics

Engineering staff over 100 engineers Resolution Medical engineering team

Expected close year 2026 Acquisition closing timeline pending approvals

Market Reality Check

Price: $61.21 Vol: Volume 3,449,802 is 1.72x...

high vol

$61.21 Last Close

Volume Volume 3,449,802 is 1.72x the 20-day average of 2,004,119, indicating elevated trading activity ahead of this acquisition news. high

Technical Shares at $61.21 are trading above the 200-day MA of $55.45 and sit 12.37% below the 52-week high of $69.85.

Peers on Argus

CG slipped 0.11% while peers showed mixed moves: TPG -2.67%, OWL -2.14%, TROW +0...

CG slipped 0.11% while peers showed mixed moves: TPG -2.67%, OWL -2.14%, TROW +0.35%, NTRS +0.65%, RJF +0.33%. With no peers in the momentum scanner, trading appears stock-specific rather than a sector-wide rotation.

Previous Acquisition Reports

5 past events · Latest: Jan 06 (Positive)

Same Type Pattern 5 events

Date	Event	Sentiment	Move	Catalyst
Jan 06	MedTech acquisition	Positive	+2.5%	Resonetics bought Med-Ally assets to deepen neuromodulation and implant offerings.
Nov 12	Defense acquisition	Positive	+2.2%	ARMADA acquired Poseidon Industrial to broaden U.S. Navy modernization services.
Sep 29	MedTech acquisition	Positive	+1.4%	Resonetics bought Eden Holdings to add micro-molding and advanced machining.
Aug 26	Software acquisition	Positive	+1.9%	Carlyle agreed to acquire intelliflo, a cloud practice management platform.
Jul 22	IT services buyout	Positive	-0.1%	Carlyle took a majority stake in Adastra, an AI and data consultancy.

Pattern Detected

Acquisition announcements for CG-linked platforms have generally seen modestly positive next-day moves, with only one slight negative reaction among recent deals.

Recent Company History

Over the past six months, Carlyle-linked entities have repeatedly used acquisitions to expand capabilities across technology, defense, and MedTech. Deals for Med-Ally, Eden Holdings, Adastra, and intelliflo all targeted higher-growth, specialized niches, and four of the last five acquisition headlines saw positive 24-hour price reactions of 1.41–2.53%. Today’s Resonetics–Resolution Medical agreement continues this pattern of bolt-on expansion in complex medical devices and neuromodulation, but the immediate share reaction has been comparatively muted.

Historical Comparison

acquisition

+1.6 %

Average Historical Move

Historical Analysis

In the last 5 acquisition headlines tied to CG, average next-day moves were about +1.61%. Today’s roughly flat -0.11% reaction is softer than that pattern.

Typical Pattern

Recent activity shows a consistent use of acquisitions to extend CG-backed platforms into specialized areas such as neuromodulation, injection micro-molding, defense integration, and software, with Resonetics’ new deal adding scale and capabilities in complex medical devices.

Market Pulse Summary

This announcement highlights Resonetics’ plan to acquire Resolution Medical, adding more than 240 em...

Analysis

This announcement highlights Resonetics’ plan to acquire Resolution Medical, adding more than 240 employees and over 100 engineers plus capabilities in neuromodulation and structural heart devices. It follows multiple CG-backed acquisitions across MedTech and software, where prior deals typically saw modest positive stock moves averaging +1.61%. Investors may focus on regulatory approvals, integration of design and cleanroom production capacity, and how this fits with Resonetics’ earlier Med-Ally and Eden transactions.

Key Terms

neuromodulation, structural heart, interventional cardiology, cleanroom

4 terms

neuromodulation medical

"high-growth therapeutic markets, including neuromodulation, structural heart, and interventional"

Neuromodulation is the use of devices or targeted treatments to change how nerves or brain circuits send signals, much like adjusting the volume or tuning on an audio system to alter what you hear. For investors, it matters because these therapies can treat chronic conditions (pain, movement disorders, depression) where existing medicines fall short, creating potential markets, regulatory milestones, and durable revenue streams if technologies prove safe and effective.

structural heart medical

"high-growth therapeutic markets, including neuromodulation, structural heart, and interventional"

Structural heart describes medical devices and treatments that fix or replace the heart’s valves, walls, chambers and other physical parts — essentially the mechanical “plumbing and doors” of the heart rather than electrical or artery-focused care. It matters to investors because advances, regulatory approvals, and shifts from open surgery to less invasive procedures can quickly change sales, profit margins and adoption rates for companies that make these devices, much like a new, more efficient tool reshaping a repair market.

interventional cardiology medical

"including neuromodulation, structural heart, and interventional cardiology to current Resonetics"

Interventional cardiology is a medical specialty that treats heart and blood-vessel problems using thin tubes and small tools inserted through a blood vessel instead of open surgery — for example placing stents or inflating tiny balloons to open a clogged artery. Investors care because it drives demand for specialized devices, procedures and training, and therefore revenue growth, regulatory review and adoption rates matter much like a new car part that must prove safe, effective and widely used before sales scale.

cleanroom technical

"high-quality design engineering, new product introduction (NPI), and cleanroom production capabilities."

A cleanroom is a tightly controlled workspace where air, particles, microbes, temperature and humidity are kept within strict limits to prevent contamination during manufacturing, testing or research—commonly used for pharmaceuticals, biotech, medical devices and semiconductors. Investors care because a well-designed and operated cleanroom reduces product defects, supports regulatory approval and enables reliable scale-up; think of it as a sterile kitchen that protects delicate recipes, lowering recall risk and helping preserve revenue and margins.

AI-generated analysis. Not financial advice.

NASHUA, N.H., Jan. 27, 2026 /PRNewswire/ -- Resonetics announced today that it has signed an agreement to acquire Resolution Medical, a leading provider of integrated design and manufacturing solutions for complex medical devices. Resolution Medical is headquartered in Fridley, MN, with additional operations in the Netherlands, and is currently owned by Arcline Investment Management.

The transaction adds complementary capabilities in high-growth therapeutic markets, including neuromodulation, structural heart, and interventional cardiology to current Resonetics offerings. The acquisition is expected to close in 2026, pending regulatory approvals and customary closing conditions.

"Resolution Medical is an exceptional organization with deep technical expertise, a strong innovation culture, and a proven track record in designing and developing complex medical devices for the most innovative companies," said Kevin Kelly, CEO of Resonetics. "This acquisition will enhance our ability to deliver fully integrated solutions for customers in high-growth markets like neuromodulation and structural heart and supports our vision of becoming the most comprehensive partner in the medical device industry."

"This acquisition represents the ideal outcome for our customers and for our employees. Our customers will benefit from access to deeper capabilities and a more integrated, expansive partner," said Peter Herman, CEO of Resolution Medical. "By joining Resonetics, our employees also gain access to the skills, resources, and opportunities of a larger organization. Resolution Medical will be able to operate at greater scale and deliver enhanced solutions to our customers while continuing to support their programs with the same teams, expertise, and commitment they rely on today."

Resolution Medical brings more than 240 employees, including over 100 engineers, and a strong reputation for delivering high-quality design engineering, new product introduction (NPI), and cleanroom production capabilities. The company supports a wide range of Class II and III devices and has built deep customer relationships, particularly in the neuromodulation and structural heart markets.

Backed by funds managed by global investment firm Carlyle and leading private equity firm GTCR, Resonetics provides end-to-end product development and manufacturing services, from prototyping through high-volume production. The addition of Resolution Medical enhances Resonetics' ability to support customers with increasingly complex devices across the full product lifecycle.

Until the transaction closes, Resonetics and Resolution Medical will continue to operate independently. Nelson Mullins Riley & Scarborough acted as legal advisor to Resonetics.

About Resonetics
Founded in 1987, Resonetics is a pioneer in advanced engineering and manufacturing solutions for the medical device industry. Resonetics is a leader in laser processing, nitinol manufacturing, thin-wall stainless steel, nitinol & precious metal tubing, and photochemical machining. With strategically located LightSpeed Labs® and AGILE Product Development® centers, Resonetics is committed to quality, speed, innovation, and a great customer experience. The company is ISO 13485:2016 certified with 18 facilities and more than 3,000 associates in the United States, Canada, Costa Rica, Israel, and Switzerland. Resonetics is backed by leading private equity firms Carlyle and GTCR. Learn more at www.resonetics.com.

About GTCR
Founded in 1980, GTCR is a leading private equity firm that invests behind The Leaders Strategy™ – finding and partnering with management leaders in core domains to identify, acquire and build market-leading companies through organic growth and strategic acquisitions. GTCR is focused on investing in transformative growth in companies in the Business & Consumer Services, Financial Services & Technology, Healthcare and Technology, Media & Telecommunications sectors. Since its inception, GTCR has invested more than $30 billion in approximately 300 companies, and the firm currently manages approximately $50 billion in equity capital. GTCR is based in Chicago with offices in New York and West Palm Beach. For more information, please visit www.gtcr.com. Follow us on LinkedIn.

About Carlyle
Carlyle (NASDAQ: CG) is a global investment firm with deep industry expertise that deploys private capital across its business and operates through three segments: Global Private Equity, Global Credit, and Carlyle AlpInvest. With $474 billion of assets under management as of September 30, 2025, Carlyle's purpose is to invest wisely and create value on behalf of its investors, portfolio companies, and the communities in which we live and invest. Carlyle employs more than 2,400 people in 27 offices across four continents. Further information is available at carlyle.com. Follow Carlyle on LinkedIn at The Carlyle Group and on X at @OneCarlyle.

View original content to download multimedia:https://www.prnewswire.com/news-releases/resonetics-to-acquire-resolution-medical-expanding-capabilities-in-neuromodulation-and-structural-heart-markets-302671594.html

SOURCE Resonetics, LLC

FAQ

What did Resonetics (CG) announce on January 27, 2026?

Resonetics announced it signed an agreement to acquire Resolution Medical, expanding capabilities in neuromodulation and structural heart markets.

When is the Resonetics (CG) acquisition of Resolution Medical expected to close?

The acquisition is expected to close in 2026, pending regulatory approvals and customary closing conditions.

How many employees does Resolution Medical bring to Resonetics (CG)?

Resolution Medical brings more than 240 employees, including over 100 engineers.

Which markets and device classes does Resolution Medical support for Resonetics (CG)?

Resolution Medical supports high-growth markets including neuromodulation and structural heart, and manufactures Class II and III devices.

Will Resonetics and Resolution Medical operate together immediately after the announcement?

No; until the transaction closes, both companies will continue to operate independently.

Did Resonetics (CG) disclose the purchase price for Resolution Medical?

No; the announcement did not disclose any purchase price or financial terms.